April 18 (Reuters) - ANI Pharmaceuticals Inc ::ANI PHARMACEUTICALS ANNOUNCES APPROVAL OF MORPHINE SULFATE ORAL SOLUTION.ANI PHARMACEUTICALS INC - RECEIVED APPROVAL FROM U.S. FDA OF ITS ANDA FOR MORPHINE SULFATE ORAL SOLUTION 10MG/5ML, 20MG/5ML AND 100MG/5ML.
Full Article
Dec 29 (Reuters) - Ani Pharmaceuticals Inc ::ANI PHARMACEUTICALS ENTERS FIVE-YEAR $125 MILLION SENIOR SECURED CREDIT FACILITY WITH CITIZENS BANK.ANI PHARMACEUTICALS SAYS FACILITY ALSO INCLUDES A $50 MILLION SENIOR SECURED REVOLVING CREDIT FACILITY WHICH REMAINS UN-DRAWN.ANI PHARMA SAYS TERM LOAN ALSO USED TO REFINANCE EXISTING INDEBTEDNESS OF $25 MILLION.
Full Article
Dec 29 (Reuters) - Ani Pharmaceuticals Inc ::ANI PHARMACEUTICALS ACQUIRES FOUR NDAS FROM ASTRAZENECA FOR $46.5 MILLION.ANI PHARMACEUTICALS INC - ACQUISITIONS WERE FUNDED THROUGH A COMBINATION OF CASH AND DEBT.ANI PHARMACEUTICALS SAYS ADDITION OF ASSETS WILL BE MATERIAL TO REVENUE AND EBITDA IN 2018.
Full Article
Nov 2 (Reuters) - ANI Pharmaceuticals Inc :ANI Pharmaceuticals reports record third quarter and year-to-date 2017 results and narrows full year guidance.Q3 adjusted Non-GAAP earnings per share $1.11.Q3 GAAP earnings per share $0.40.Q3 revenue $48.2 million versus I/B/E/S view $48.1 million.Q3 earnings per share view $0.99 -- Thomson Reuters I/B/E/S.ANI Pharmaceuticals Inc sees for full year 2017 net revenues $181 million to $183 million.ANI Pharmaceuticals Inc sees for full year 2017 adjusted Non-GAAP diluted earnings per share $3.83 to $4.00.Q3 earnings per share view $0.99, revenue view $48.1 million -- Thomson Reuters I/B/E/S.FY2017 earnings per share view $3.84, revenue view $182.1 million -- Thomson Reuters I/B/E/S.ANI Pharmaceuticals Inc - ANI intends to request a meeting with fda in Q4 of 2017 to present its regulatory filing plan.
Full Article
Ani Pharmaceuticals Inc : Ani pharmaceuticals acquires inderal® xl and innopran xl® . Ani pharmaceuticals inc - acquisitions were funded through a combination of cash and debt . Ani pharma - has begun selling inderal xl 80mg, 120mg sustained release capsules, innopran xl 80mg, 120mg sustained release capsules under current labels . Ani pharma - will transition inderal xl and innopran xl to ani label at a future date . Ani pharmaceuticals inc - acquired inderal xl from cranford pharmaceuticals, llc and innopran xl from holmdel pharmaceuticals lp .Ani pharmaceuticals inc- acquired inderal xl from cranford pharmaceuticals, llc and innopran xlfrom holmdel pharmaceuticals lp.
Full Article
ANI Pharmaceuticals : Reports record second quarter results and increases full year 2016 guidance . Q2 GAAP earnings per share $0.10 . Q2 earnings per share view $0.77 -- Thomson Reuters I/B/E/S . Q2 adjusted non-GAAP earnings per share $1.11 . Q2 revenue $31.3 million versus I/B/E/S view $27.6 million . Increases full year 2016 guidance . Sees full-year 2016 revenue $119 million to $134 million . Sees full-year 2016 adjusted non-GAAP earnings per share $4.00 to $4.25 .Full-year 2016 earnings per share view $3.63, revenue view $124.2 million -- Thomson Reuters I/B/E/S.
Full Article
ANI Pharmaceuticals Inc : ANI Pharmaceuticals announces FDA approval and immediate launch of Nilutamide tablets, the first generic competitor to Nilandron® .ANI will immediately launch product.
Full Article
ANI Pharmaceuticals Inc : ANI Pharmaceuticals announces FDA approval of oxcarbazepine tablets .ANI Pharmaceuticals Inc says has received approval from FDA of prior approval supplement for oxcarbazepine tablets, 150mg, 300mg and 600mg.
Full Article
Earnings vs. 
Estimates